Pharsight

Shionogi Inc patents expiration

1. Fetroja patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9238657 SHIONOGI INC Cephalosporin having catechol group
Nov, 2033

(10 years from now)

US10004750 SHIONOGI INC Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
Sep, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9949982 SHIONOGI INC Preparation containing cephalosporin having a catechol moiety
Sep, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 14, 2024
New Indication (I) Sep 25, 2023
Generating Antibiotic Incentives Now (GAIN) Nov 14, 2029

Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient

NCE-1 date: 2028-11-14

Market Authorisation Date: 14 November, 2019

Treatment: Method of treating bacterial infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

FETROJA family patents

Family Patents

2. Mulpleta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7601746 SHIONOGI INC Compounds exhibiting thrombopoietin receptor agonism
Sep, 2024

(11 months from now)

US8889722 SHIONOGI INC Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
Jul, 2028

(4 years from now)

US8530668 SHIONOGI INC Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
Jan, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9427402 SHIONOGI INC Preparation for improving solubility of poorly soluble drug
Sep, 2031

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 31, 2023

Drugs and Companies using LUSUTROMBOPAG ingredient

NCE-1 date: 2022-07-31

Market Authorisation Date: 31 July, 2018

Treatment: Treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure

Dosage: TABLET;ORAL

More Information on Dosage

MULPLETA family patents

Family Patents

3. Ulesfia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6793931 SHIONOGI INC Ectoparasite asphyxiator compositions and methods for their applications
Jul, 2022

(1 year, 2 months ago)

US7294342 SHIONOGI INC Ectoparasite asphyxiator compositions and methods for their application
May, 2024

(7 months from now)

Drugs and Companies using BENZYL ALCOHOL ingredient

Market Authorisation Date: 09 April, 2009

Treatment: Topical treatment of lice infestations

Dosage: LOTION;TOPICAL

How can I launch a generic of ULESFIA before it's drug patent expiration?
More Information on Dosage

ULESFIA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic